Prelude Therapeutics Inc (PRLD) - News Archive

Prelude Therapeutics Inc: A New Chapter in Targeted Cancer Therapies Amid Financial Challenges and Promising Preclinical Data Prelude Therapeutics Inc, a biotechnology company dedicated to transforming the treatment lan...

Prelude Therapeutics, a leader in developing targeted therapies for various malignancies, has reported encouraging preliminary results from ongoing clinical trials involving two of its key investigational compounds, PRT...

Prelude Therapeutics Inc. is poised to make a significant impact in the field of oncology with its novel therapeutic candidate, PRT3789, which is set to be presented at the prestigious 36th EORTC-NCI-AACR Symposium on O...

Prelude Therapeutics Inc. has recently garnered attention within the pharmaceutical sector due to their innovative therapeutic approach targeting cancer through the degradation of the SMARCA2 protein. Notably, their inv...

Prelude Therapeutics Inc (PRLD) Stock: A SWOT AnalysisThe stock of Prelude Therapeutics Inc (NASDAQ: PRLD) has experienced a significant increase of 14.86% compared to its last closing price of 3.97. Despite this recent...

In a groundbreaking move set to potentially revolutionize the landscape of oncology, Prelude Therapeutics has announced a collaborative clinical initiative with Merck to evaluate the efficacy of its leading-edge molecul...

The American Association for Cancer Research (AACR) held its annual meeting in 2024, where an exciting breakthrough in cancer research was unveiled by Prelude Therapeutics Inc. The event provided a platform to highlight...

In the competitive world of pharmaceutical research, companies constantly strive to innovate and develop cutting-edge therapies that can revolutionize patient care. In this article, we delve into the latest update from...

Prelude Therapeutics Incorporated, a leading clinical-stage precision oncology company, recently unveiled its plans for a private placement earmarked to raise an estimated $25 million in gross proceeds. This funding wil...